3/2
01:20 pm
dyn
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing [Yahoo! Finance]
Low
Report
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing [Yahoo! Finance]
3/2
01:05 pm
dyn
Dyne Therapeutics (DYN) had its "overweight" rating reaffirmed by Morgan Stanley.
Low
Report
Dyne Therapeutics (DYN) had its "overweight" rating reaffirmed by Morgan Stanley.
3/2
07:42 am
dyn
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
3/2
07:30 am
dyn
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Medium
Report
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2/25
08:03 am
dyn
Dyne Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Dyne Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/25
07:30 am
dyn
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Dyne Therapeutics to Participate in Upcoming Investor Conferences
2/22
04:00 pm
dyn
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
Medium
Report
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
2/16
12:38 pm
dyn
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry [Yahoo! Finance]
Low
Report
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry [Yahoo! Finance]
2/2
09:17 am
dyn
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors [Yahoo! Finance]
Medium
Report
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors [Yahoo! Finance]
1/27
04:12 am
dyn
Dyne Therapeutics: 2026 Catalysts Point To Further Upside [Seeking Alpha]
Low
Report
Dyne Therapeutics: 2026 Catalysts Point To Further Upside [Seeking Alpha]
1/20
10:24 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $17.00 to $16.00. They now have a "neutral" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $17.00 to $16.00. They now have a "neutral" rating on the stock.
1/20
07:30 am
dyn
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
Low
Report
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
1/7
07:30 am
dyn
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
High
Report
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
12/28
01:08 am
dyn
Dyne Therapeutics (NASDAQ:DYN) was downgraded by analysts at
Wall Street
Low
Report
Dyne Therapeutics (NASDAQ:DYN) was downgraded by analysts at
Wall Street
12/23
07:30 am
dyn
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
Low
Report
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
12/22
07:02 am
dyn
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) [Yahoo! Finance]
Medium
Report
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) [Yahoo! Finance]
12/20
01:30 am
dyn
Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at
Wall Street Ze
Medium
Report
Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at
Wall Street Ze
12/15
09:11 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
12/11
07:03 pm
dyn
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial [Yahoo! Finance]
Low
Report
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial [Yahoo! Finance]
12/11
04:05 pm
dyn
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Low
Report
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
12/11
08:44 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at Stifel Nicolaus from $36.00 to $39.00. They now have a "buy" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at Stifel Nicolaus from $36.00 to $39.00. They now have a "buy" rating on the stock.
12/10
11:43 am
dyn
Dyne Therapeutics: Why The $350M Public Offering Was Critical [Seeking Alpha]
Low
Report
Dyne Therapeutics: Why The $350M Public Offering Was Critical [Seeking Alpha]
12/10
07:20 am
dyn
Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.
12/9
09:42 pm
dyn
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
Medium
Report
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
12/9
01:03 pm
dyn
Dyne Therapeutics (NASDAQ:DYN) was given a new $23.00 price target on by analysts at Tudor Pickering.
Medium
Report
Dyne Therapeutics (NASDAQ:DYN) was given a new $23.00 price target on by analysts at Tudor Pickering.